The HMGXB3 Knockout HEK293T Polyclonal Cells product consists of a heterogeneous pool of HEK293T cells that have undergone CRISPR/Cas9-mediated targeted disruption of the HMGXB3 gene. This polyclonal knockout population provides a genetically diverse loss-of-function model, generated without single-cell cloning, thereby preserving a broad representation of editing outcomes. The knockout approach enables researchers to interrogate HMGXB3-dependent cellular functions in a human cell background, avoiding clonal artifacts and maintaining population-level heterogeneity that can be critical for certain experimental designs. This product is supplied as a ready-to-use polyclonal cell pool, suitable for downstream applications in signaling and gene regulation studies.
The host HEK293T cell line is derived from human embryonic kidney epithelial cells and is stably transformed with the SV40 large T antigen. This immortalized cell line is widely employed in biomedical research due to its high transfectability, robust protein expression capacity, and permissiveness for lentiviral and retroviral production. HEK293T cells retain functional TGF-beta signaling machinery, making them an appropriate host for studying this pathway. Their epithelial origin and well-characterized growth properties further support applications in functional genomics, drug discovery, and cell-based assays, providing a reliable and reproducible cellular context for gene perturbation experiments.
HMGXB3 encodes a DNA-binding protein that functions as a transcriptional co-regulator, known to modulate transforming growth factor-beta (TGF-beta) signaling through direct interaction with SMAD2 and SMAD3. Within the TGF-beta pathway, upon ligand-induced receptor activation, SMAD2/3 become phosphorylated and translocate to the nucleus, where HMGXB3 associates with them to regulate the transcription of target genes such as SERPINE1, CTGF, MMP9, SNAI1, and ZEB1. HMGXB3 is thus positioned downstream of TGF-beta ligands (TGFB1, TGFB2, TGFB3) and the receptor complex (TGFBR1/2), and acts as a cofactor facilitating the expression of genes involved in epithelial-mesenchymal transition, extracellular matrix remodeling, and cell proliferation. It also interacts with DNA and histones, linking chromatin organization to TGF-beta-responsive gene programs.
Disruption of HMGXB3 in HEK293T cells is expected to perturb TGF-beta-dependent transcriptional programs, offering a valuable model to dissect the role of this co-regulator in signal transduction. The knockout cells enable the examination of altered gene expression profiles, chromatin binding dynamics, and functional outcomes such as cell migration and proliferation in a well-defined epithelial background. Since HEK293T cells are frequently used for TGF-beta research, this polyclonal knockout population allows for the assessment of pathway responses without the compensatory effects that can arise in clonal isolates. Consequently, it serves as a powerful tool for investigating both canonical and non-canonical TGF-beta signaling events, as well as the broader impact of HMGXB3 on gene regulation beyond this pathway.
Typical research applications include functional genomics screens, analysis of TGF-beta-induced epithelial-mesenchymal transition, cancer biology studies focusing on tumor progression and metastasis, fibrosis research examining extracellular matrix regulation, and drug screening for TGF-beta pathway inhibitors. The cells can be employed in a variety of assays such as western blotting for total and phospho-SMAD2/3, RT-qPCR for downstream targets, ChIP-qPCR to assess SMAD and HMGXB3 chromatin occupancy, luciferase reporter assays with SMAD-responsive elements, cell proliferation and wound healing assays, and immunofluorescence for SMAD2/3 subcellular localization. This knockout resource provides a robust platform for mechanistic studies and therapeutic development. For further details, please contact Ascent Research.
